Landiolol
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Landiolol: From an Undocumented Original Indication to Lingual-Facial-Buccal Dyskinesia
One-Sentence Summary
Landiolol’s original approved indication is not recorded in the current evidence pack (data gap), though it is known from the collected rationale notes to be an ultra-short-acting, highly β1-selective adrenergic antagonist (pharmacologically similar to esmolol). The TxGNN model’s top-ranked prediction is Lingual-Facial-Buccal Dyskinesia, but this is supported by 0 clinical trials and 0 publications — and the evidence pack’s own mechanistic rationale explicitly flags this specific link as biologically strained (the disorder is primarily dopaminergic, not adrenergic). This candidate should be treated as an unvalidated model signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current evidence pack (no original indications or MOA on file) |
| Predicted New Indication | Lingual-Facial-Buccal Dyskinesia |
| TxGNN Prediction Score | 99.11% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| Market Status (Taiwan) | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Landiolol is not confirmed in this evidence pack (flagged as a High-severity data gap). However, the rationale notes attached to other candidates in this same prediction set describe Landiolol as an ultra-short-acting, highly selective β1-adrenergic receptor antagonist, pharmacologically comparable to esmolol and administered only by IV infusion with a half-life of minutes.
No original indication is recorded, so the usual comparison between “proven original use” and “predicted new use” cannot be made here — this is a genuine gap, not an omission.
For the top-ranked candidate specifically, the evidence pack’s own repurposing rationale argues against mechanistic plausibility: lingual-facial-buccal dyskinesia is understood to arise primarily from chronic dopamine-receptor blockade (e.g., antipsychotic-induced tardive dyskinesia), a pathway centered on the dopaminergic system rather than adrenergic β1 signaling. The rationale text itself characterizes the β1-antagonist link to this disorder as having “no clear mechanistic association” — a high TxGNN score without a coherent pharmacological story. By contrast, a lower-ranked candidate in this same set (primary orthostatic tremor, rank 6) has a more conventional mechanistic basis, since β-blockers are established treatment for tremor disorders — though it is also unsupported by any trial or literature evidence and limited by Landiolol’s IV-only, ultra-short-acting profile, which is unsuited to chronic outpatient management.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Landiolol currently holds no Taiwan marketing authorizations (market status: not marketed; 0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all currently unavailable in this evidence pack; a Blocking-severity gap has been flagged for TFDA label/warning data.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- All six ranked candidates in this prediction set carry Evidence Level L5 (model score only, zero supporting trials or literature) and are staged at S0. For the top-ranked candidate, the mechanistic rationale documented in the evidence pack itself argues against plausibility rather than for it.
- A Blocking-severity data gap (TFDA warnings/contraindications) currently prevents this candidate from even entering the S1 safety pre-screen.
To proceed, the following is needed:
- TFDA label data (warnings, contraindications) — required before any S1 safety evaluation can begin (Blocking gap)
- Verified mechanism-of-action data from DrugBank (High-severity gap)
- Preclinical or mechanistic studies linking β1-adrenergic blockade to the proposed movement-disorder pathway, given the documented dopaminergic (not adrenergic) basis of the top-ranked indication
- Consider re-evaluating whether a mechanistically stronger candidate from this set (e.g., primary orthostatic tremor) merits prioritization over the raw TxGNN top rank
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.